Veru Announces New England Journal of Medicine Evidence

- Phase 3 Clinical Study Met Primary and Key Secondary Endpoints - - Primary Endpoint: Sabizabulin Treatment Showed Statistically Significant and...

Related Keywords

Miami ,Florida ,United States ,Bulgaria ,Houston ,Texas ,Mexico ,Argentina ,Brazil ,Colombia ,Mitchell Steiner ,Samuel Fisch ,Tara Gonzales ,Alan Skolnick ,Anthony Berry ,Eli Lilly ,Gary Barnette ,Data Safety Monitoring Committee ,Phd Research ,Nasdaq ,Exchange Commission ,Company Submitted Request For Emergency Use Authorization ,Company Form ,Affairs Infectious Diseases Franchise ,Corporate Communications ,Veru Inc ,Memorial Hermann City Medical Center ,Study Met Primary ,Key Secondary Endpoints ,Clinically Meaningful ,Deaths Compared ,Moderate Severe Hospitalized ,Secondary Endpoints ,Sabizabulin Treatment ,Clinically Meaningful Reduction ,Mechanical Ventilation ,Well Tolerated ,More Favorable Safety Profile Compared ,Submitted Request ,Emergency Use Authorization ,New England Journal ,Independent Data Safety Monitoring Committee ,Medicine Evidence ,Chief Scientific Officer ,Principal Investigator ,Chief Executive Officer ,Fast Track ,Private Securities Litigation Reform Act ,Investor Relations ,Medical Affairs Infectious Diseases ,Nasdaq Veru ,